SB02024
Based on 1 publication(s) in Google Scholar
SB02024 is a potent and orally active VPS34 inhibitor. SB02024 inhibits Vps34 kinase activity. SB02024 induces CCL5 and CXCL10 via STAT1/IRF7. SB02024 shows anticancer activity.
For research use only. We do not sell to patients.
- Purity: 99.70%
- CAS No.: 2126737-28-6
- Formula: C16H22F3N3O2
- Molecular Weight:345.36
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) SB02024
More
Biological Activity
|
Vps34 |
STAT1 |
SB02024 (5 μM, 48 h) induces CCL5 and CXCL10 via STAT1/IRF7 in B16-F10 and CT26 tumor cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:B16-F10 and CT26 tumor cells
-
Concentration:5 μM
-
Incubation Time:48 h
-
Result:Significantly up-regulates both Ccl5/Rantes and Cxcl10/IP10 mRNA and their corresponding secreted protein levels in YUMM cells, B16-F10 and CT26 tumor cells. Showed an induction of phospho-signal transducer and activator of transcription 1 (pSTAT1) and increased protein and mRNA expression of STAT1, IRF1 and IRF7.
SB02024 increases the levels of CCL5 and CXCL10 in the blood plasma of B16-F10 and CT26 tumor-bearing mice, but dose not increase CCL5 or CXCL10 levels in the blood of non-tumor-bearing mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6, BALB/C, immunodeficient NSG mice (7 weeks old)[1]
-
Dosage:20 mg/kg
-
Administration:Oral gavage
-
Result:Decreased the tumor growth and weight of B16-F10 and CT26 and prolonged the survival of tumor-bearing mice.
Chemical Information
-
CAS No. 2126737-28-6
-
Appearance Solid
-
Molecular Weight 345.36
-
Formula C16H22F3N3O2
-
Color White to off-white
-
SMILES
O=C1C=C(N2[C@H](C)COCC2)C=C(N3[C@@H](C(F)(F)F)CCCC3)N1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
DMSO : 100 mg/mL (289.55 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (14.48 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (14.48 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Noman MZ, et al. Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy. Sci Adv. 2020 Apr 29;6(18):eaax7881. [Content Brief]
[2]. Yu Y, et al. Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti-tumor efficacy. Mol Oncol. 2024 Mar 20. [Content Brief]
[3]. Bassam Claude JANJI, et al. Biomarker. Patent WO2020008046 A1.
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8955 mL | 14.4776 mL | 28.9553 mL | 72.3882 mL |
| 5 mM | 0.5791 mL | 2.8955 mL | 5.7911 mL | 14.4776 mL | |
| 10 mM | 0.2896 mL | 1.4478 mL | 2.8955 mL | 7.2388 mL | |
| 15 mM | 0.1930 mL | 0.9652 mL | 1.9304 mL | 4.8259 mL | |
| 20 mM | 0.1448 mL | 0.7239 mL | 1.4478 mL | 3.6194 mL | |
| 25 mM | 0.1158 mL | 0.5791 mL | 1.1582 mL | 2.8955 mL | |
| 30 mM | 0.0965 mL | 0.4826 mL | 0.9652 mL | 2.4129 mL | |
| 40 mM | 0.0724 mL | 0.3619 mL | 0.7239 mL | 1.8097 mL | |
| 50 mM | 0.0579 mL | 0.2896 mL | 0.5791 mL | 1.4478 mL | |
| 60 mM | 0.0483 mL | 0.2413 mL | 0.4826 mL | 1.2065 mL | |
| 80 mM | 0.0362 mL | 0.1810 mL | 0.3619 mL | 0.9049 mL | |
| 100 mM | 0.0290 mL | 0.1448 mL | 0.2896 mL | 0.7239 mL |
SB02024 Related Classifications
HY-122891 Related Classifications
Powered by Bioz